Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to -$315,000.

  • Allogene Therapeutics' Gains from Investment Securities rose 94.75% to -$315,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $500,000, marking a year-over-year decrease of 85.09%. This contributed to the annual value of -$4.3 million for FY2024, which is 161.13% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Gains from Investment Securities stood at -$315,000, which was down 116.34% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Gains from Investment Securities ranged from a high of $28.2 million in Q2 2022 and a low of -$6.0 million during Q3 2024.
  • For the 3-year period, Allogene Therapeutics' Gains from Investment Securities averaged around $390,900, with its median value being $27,500 (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 27,861.40% in 2021, then slumped by 303.74% in 2024.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Gains from Investment Securities stood at $4.1 million in 2021, then slumped by 80.46% to $28.2 million in 2022, then tumbled by 99.65% to $4.0 million in 2023, then plummeted by 117.20% to -$688,000 in 2024, then soared by 94.75% to -$315,000 in 2025.
  • Its last three reported values are -$315,000 in Q3 2025, $1.9 million for Q2 2025, and -$425,000 during Q1 2025.